In addition, cost–benefit analysis should be integrated to compare the economic efficiency of YLDJJ combined with rTMS and pharmacological treatment, especially in regions with limited resources and a continuously increasing burden of stroke in the elderly population (1); Finally, as predictors of efficacy, serum neuroinflammatory markers, such as IL-1β, and TNF-α, should be verified to provide a basis for phenotypic mechanism stratification of CRPS-I in the elderly. This evidence concerns the gene IL1B and Stroke.